Targeted cancer stem cell therapies start with proper identification of the target - Letter

Molecular Cancer Research

Volumn 8, Issue 2, 2010, Pages 291-

  Vlashi, Erina ^a   Pajonk, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB;

CANCER CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CELL THERAPY; CYTOTOXICITY; GENE TARGETING; GENETIC IDENTIFICATION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; LETTER; PHENOTYPE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; CYSTEINE PROTEINASE INHIBITORS; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; LEUPEPTINS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEASOME ENDOPEPTIDASE COMPLEX; REPRODUCIBILITY OF RESULTS;

EID: 77249121753     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0505     Document Type: Letter

References (3)

1. Monticone M, Biollo E, Fabiano A, et al. z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. Mol Cancer Res 2009;7:1822-34.
2. Vlashi E, Kim K, Lagadec C, et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009;101:350-9.
3. Fan X, Khaki L, Zhu TS, et al. Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2009. Epub 2009 Nov 10.